Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's patent cliff the real test ahead?

As Merck's blockbuster Keytruda faces looming patent expiration, you need to weigh its growth pipeline against competitive pressures in oncology. This shapes investment decisions for U.S. and global readers tracking pharma leaders. ISIN: US58933Y1055

Merck & Co., Inc., trading as MRK on the NYSE, stands as a pharmaceutical powerhouse with a portfolio anchored by oncology and vaccines, but its future hinges on navigating the patent expiration of Keytruda, its top revenue driver. You, as an investor in the United States or English-speaking markets worldwide, face a critical question: can Merck's next-generation drugs and strategic expansions offset the revenue drop from generics entering the market post-2028? The company's diversified approach in immunology, cardiovascular, and animal health positions it resiliently amid industry headwinds.

Updated: 19.04.2026

By Elena Vargas, Senior Pharma Equity Analyst – Merck's oncology dominance meets pipeline challenges in a shifting market landscape.

Merck's Core Business Model and Revenue Engines

Merck operates a research-driven model focused on high-margin therapeutics, with oncology comprising over 40% of sales through drugs like Keytruda (pembrolizumab), a PD-1 inhibitor leading in lung cancer and melanoma treatments. Vaccines, including Gardasil for HPV prevention, contribute steady growth, particularly in international markets where public health initiatives boost demand. Animal health, via the Organon spin-off legacy and ongoing operations, provides defensive cash flow less tied to patent cycles.

This structure allows Merck to reinvest roughly 25-30% of revenues into R&D annually, funding a pipeline of 80+ programs across modalities like ADCs and bispecific antibodies. For you, this means exposure to both mature cash cows and innovation bets, balancing near-term stability with long-term upside in a sector where blockbusters can define decades. The model's emphasis on partnerships, such as with Moderna on cancer vaccines, amplifies reach without full development costs.

Globally, Merck targets emerging markets for volume growth in vaccines while defending premium pricing in the U.S., where Medicare negotiations pose pricing pressures. This dual focus sustains mid-single-digit revenue growth projections through the decade, assuming pipeline successes materialize as planned.

Key Products Driving Market Leadership

Keytruda remains Merck's cornerstone, generating over $25 billion in annual sales by treating multiple cancers via immunotherapy, with label expansions into earlier-stage uses extending its lifecycle. Winrevair, a recent cardiovascular approval for pulmonary arterial hypertension, marks entry into rare diseases with high pricing power and orphan status protections. Gardasil franchise exceeds $8 billion yearly, fueled by male and adult indications alongside adolescent dosing.

Pipeline highlights include MK-1084, an oral KRAS inhibitor for lung cancer, and subcutaneous Keytruda formulations to ease administration burdens on healthcare systems. These innovations target immuno-oncology dominance against rivals like Bristol Myers Squibb's Opdivo. For investors, this portfolio mix offers diversified bets: Keytruda for current dominance, Winrevair for new growth vectors, and vaccines for recurring demand.

In animal health, Bravecto for parasite control and poultry vaccines sustain leadership, lessening reliance on human pharma cycles. Merck's focus on biologics manufacturing scale-up ensures supply chain resilience, critical as biosimilars loom.

Competitive Position in Pharma Landscape

Merck holds a strong moat in immuno-oncology, where Keytruda's best-in-class profile and extensive data package deter quick erosion, even as Roche's Tecentriq and Regeneron's Libtayo compete. In vaccines, Gardasil's near-monopoly in HPV stems from first-mover advantage and superior efficacy data versus GSK's Cervarix. Diversification into cardiovascular with Winrevair differentiates from pure-play oncology peers like Exelixis or Seagen (now Pfizer).

Strategic acquisitions, such as Acceleron for PAH assets, bolster gaps without overpaying, maintaining a leaner balance sheet than acquisitive rivals like Pfizer. Merck's global footprint, with 70% ex-U.S. sales, mitigates U.S.-centric risks like drug pricing reforms. You benefit from this positioning as it supports consistent dividend growth, now at 50+ years, appealing for income-focused portfolios.

Industry tailwinds like aging populations and rising cancer incidence favor Merck's focus areas, though execution on combination therapies will determine leadership retention.

Why Merck Matters for U.S. and Global Investors

For readers in the United States, Merck's heavy U.S. revenue exposure (about 50%) ties it to domestic healthcare policy, including Inflation Reduction Act negotiations on Part D drugs, yet its innovation premium justifies sustained pricing. English-speaking markets worldwide, from Canada to Australia and the UK, mirror U.S. trends in value-based care, amplifying Merck's reimbursement successes. As a Dow component, MRK offers broad market beta with defensive pharma qualities during volatility.

You gain tax-efficient dividends yielding around 3%, plus buyback support, ideal for retirement accounts prevalent in U.S. investing. Globally, Merck's vaccine push aligns with public health spending in markets like the UK NHS and Australian PBS, ensuring volume stability. This relevance underscores why tracking Merck helps you navigate healthcare sector rotations amid economic shifts.

Compared to European peers like Novartis, Merck's U.S.-centric R&D efficiency drives higher margins, benefiting dollar-denominated portfolios across English-speaking regions.

Analyst Views on Merck Stock

Reputable firms like JPMorgan and BofA Securities maintain positive outlooks on Merck, citing pipeline depth beyond Keytruda as a buffer against patent losses, with consensus targets implying 15-20% upside from current levels. They highlight Winrevair's peak sales potential exceeding $4 billion and subcutaneous Keytruda's adherence benefits in community settings. However, some like Morningstar note valuation premiums if growth moderates, recommending holds for conservative investors.

Recent coverage from Wells Fargo emphasizes combo regimens like Keytruda-Lenvima in endometrial cancer, projecting sustained double-digit oncology growth into 2030. Analysts converge on buy ratings from institutions such as RBC Capital, focusing on undervalued animal health and emerging CVD franchises. For you, these views signal confidence in management's execution, though sensitivity to trial readouts remains a watchpoint.

Overall, the analyst community views Merck as a core holding for pharma exposure, balancing yield, growth, and resilience.

Risks and Open Questions Ahead

The paramount risk is Keytruda's 2028 patent cliff, potentially halving revenues if biosimilars capture share rapidly, as seen with Humira's U.S. erosion. Regulatory hurdles for next-gen assets, including FDA scrutiny on accelerated approvals, could delay launches and inflate costs. Pricing pressures from U.S. Medicare negotiations and ex-U.S. HTA bodies challenge margins on mature products like Januvia.

Pipeline failures represent binary risks; a stumble in KRAS or ADC programs could erode confidence, widening the gap to faster-growth biotechs. Macro factors like trade tensions impacting supply chains or recession curbing elective procedures add layers. You should monitor Phase 3 data readouts and M&A activity for signals on management's adaptability.

Competitive intensification in IO combinations poses another question: can Merck maintain share against next-gen therapies from Incyte or BeiGene? These uncertainties demand vigilant portfolio management.

What to Watch Next for Investment Decisions

Key catalysts include Q2 earnings for Keytruda uptake in adjuvant settings and Winrevair launch metrics, signaling revenue diversification pace. Regulatory milestones like s.c. Keytruda approval could unlock upside by improving patient access. M&A in ADCs or gene therapy would affirm aggressive growth posture post-Keytruda.

Track competitor readouts, such as Opdivo combos, for relative positioning, and U.S. policy updates on drug pricing. Dividend hikes or accelerated buybacks would reinforce capital return commitment. For you, aligning entry points with these events optimizes risk-reward in a volatile pharma landscape.

Ultimately, Merck's trajectory depends on pipeline conversion rates; success here positions it for outperformance versus the XBI benchmark.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.